Please login to the form below

Not currently logged in
Email:
Password:

RA

This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial. Trial adds to rivalry with AbbVie. ... drugs to help patients with active RA who don’t respond adequately to current biologics.

Latest news

More from news
Approximately 8 fully matching, plus 159 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • European CTR implementation advances ethical assessment of clinical trials European CTR implementation advances ethical assessment of clinical trials

    Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC

  • Behavioural design - it's a no-brainer Behavioural design - it's a no-brainer

    Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Lilly and NRAS launch arthritis awareness film campaign Lilly and NRAS launch arthritis awareness film campaign

    Lilly and NRAS launch arthritis awareness film campaign. Pharma firm's ‘Behind The Smile’initiative coincides with RA awareness week. ... makes people with RA feel still remains a barrier to improving the lives of those living with this disease.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • More tell, less sell: HCP-centric comms

    Burlington, MA: 2017. 11. DeJong C, Aguilar T, Tseng CW, Lin GA, Boscard in WJ, Dudley RA.

  • Biosimilars in 2018: EU doctors’ perceptions of RA drug market

    Biosimilars in 2018: EU doctors’ perceptions of RA drug market. Published in pharmaphorum October 2015 by Laurent Chanroux. ... A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. ... Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents.

  • Living with RA Report

    Living with RA Report. Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour. ... RA is a progressive and debilitating disease which affects around 3m

  • Infographic: RA Perceptions

    Download our RA Perceptions: Predicting the future of the European market infographic now ». ... Less than 25% of physicians currently report prescribing biosimilars. Overall, physicians’ awareness of pipeline agents in RA is low.

More from PMHub
Approximately 2 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics